Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.55 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.55 |
| ▸ | CDK9 | P50750 | 15/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.55 |
| ▸ | CDK2 | P24941 | 13/20 | 0.55 |
| ▸ | CDK7 | P50613 | 6/20 | 0.55 |
| ▸ | CCNH | P51946 | 6/20 | 0.55 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.55 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31666547 | 0.87 | CCNK (0.71) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL31666542 | 0.87 | CCNK (0.71) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL22900977 | 0.81 | CCNE1 (0.62) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL22900799 | 0.81 | CCNE1 (0.66) | CCNT1CDK9CCNE1CDK2CDK7 | |
| SCHEMBL22977485 | 0.79 | ULK1 (0.47) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL22900783 | 0.78 | JAK1 (0.54) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL29926869 | 0.78 | JAK1 (0.54) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL22997710 | 0.76 | ULK1 (0.55) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL22900832 | 0.76 | CCNE1 (0.70) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL30496637 | 0.76 | ULK1 (0.55) | CCNKCDK12CCNT1CDK9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK2AP2, CDK4 | CCNK 5/4885CDK12 17/4885CCNT1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.